According to The Insight Partners, the Pulmonary Function Testing Systems Market size is expected to reach $401.83 million by 2028 from $274.10 million in 2022. It is estimated to record a CAGR of 6.6% from 2022 to 2028.
Technological advancements have made spirometry much more reliable and relatively simple. Various top companies are manufacturing technology-enabled pulmonary function testing devices. For example, the Datospir Micro C spirometer, developed by Point of Care Diagnostics Pty Ltd, is a revolutionary touchscreen instrument with many features that facilitate lung function testing. The new product is a small portable spirometer with the latest technological advances, and the equipment has different configurations intended for use in clinical settings and at home. The product can also be connected to other devices through Bluetooth technologies and operates with many parameters related to FVC, VC, MVV and pulse oximetry (SPo2) options.
Top companies are partnering to scale up the diagnosis and treatment of lung diseases. For instance, in August 2022, AstraZeneca announced a partnership with Alveofit to scale up the diagnosis and treatment of lung diseases in India. The partnership between the two companies will provide Alveofit IoT-enabled handheld spirometers to clinics and last-mile hospitals that enable point-of-care spirometry that optimizes the management of different lung-associated noncommunicable diseases. Such devices will help track patients remotely and even conduct telespirometry with comprehensive care management solutions. Thus, the increase in technological advancements is likely to catalyze the growth of the global pulmonary function testing systems market during the forecast period.
A PFT consists of a clear, airtight box, soft nose clips, a mouthpiece and a small electronic machine that measures airflow (spirometer). The increase in the prevalence of respiratory disorders such as asthma, cough, and chronic obstructive pulmonary disease is promoting the growth of the hardware segment.
